Kashiv BioSciences and MS Pharma have entered into a license and supply agreement for ADL-018, Kashiv BioSciences’ biosimilar candidate to Genentech and Novartis AG’s Xolair (omalizumab) in the Middle ...
PISCATAWAY, N.J., August 05, 2025--(BUSINESS WIRE)--Kashiv BioSciences, LLC and MS Pharma today announced that the companies have entered into a license and supply agreement for ADL-018, Kashiv ...
RIYADH, Saudi Arabia, Aug. 27, 2025 /PRNewswire/ -- MS Pharma has officially inaugurated the first biologics' manufacturing facility in the Middle East, strategically located in Saudi Arabia. The ...
AMSTERDAM & ZUG, Switzerland & GDAŃSK, Poland, September 02, 2025--(BUSINESS WIRE)--Polpharma Biologics S.A. ("Polpharma Biologics"), specialized in the development and manufacturing of biosimilars, ...
A journey both personal and political, Matt Embry’s Living Proof follows the Canadian filmmaker on his quixotic quest to get some answers to a medical mystery. If no one knows the causes or cures for ...
Western drugmakers have been finding their way into the Middle East and North Africa, a market they see as having a lot of upside potential. But they are being met by some domestic companies, which ...
(Logo: http://www.newscom.com/cgi-bin/prnh/20100416/PFIZERLOGO) "As an organization working to deliver innovative solutions, we are pleased to be able to provide our ...
GlobalData on MSN
Biogen’s Tysabri to be used on England’s NHS for highly active MS
NICE has recommended Tysabri and biosimilar Tyruko as an option for patients with highly active relapsing-remitting multiple ...
TORONTO--(BUSINESS WIRE)-- FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9) (“FSD Pharma” or the “Company”), a life sciences holding company dedicated to building a portfolio of assets and ...
French pharma major Sanofi (Euronext: SAN) has received a Complete Response Letter (CRL) from the US regulator for ...
The commercialization of proposed vedolizumab (PB016), ocrelizumab (PB018) and guselkumab (PB019) biosimilars is solely the responsibility of MS Pharma, the marketing authorization holder, in ...
Polpharma Biologics S.A. (“Polpharma Biologics”), specialized in the development and manufacturing of biosimilars, today announced that it has signed licensing agreements with MS Pharma, a leading ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback